Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30002482HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30074614HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30074615HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30019425HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30018938HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30019001HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30074617HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30040824HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30040825HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30040826HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TCGA Plot Options
Drug Information
GeneITGAL
DrugBank IDDB00095
Drug NameEfalizumab
Target IDBE0000516
UniProt IDP20701
Regulation Typeantibody
PubMed IDs19170413; 17053736; 11752352; 15799683
CitationsFrampton JE, Plosker GL: Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol. 2009;10(1):51-72. doi: 10.2165/0128071-200910010-00009.@@Descamps V: [Efalizumab]. Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Wellington K, Perry CM: Efalizumab. Am J Clin Dermatol. 2005;6(2):113-8; discussion 119-20. doi: 10.2165/00128071-200506020-00006.
GroupsApproved; Investigational; Withdrawn
Direct ClassificationPeptides
SMILES
Pathways
PharmGKBPA164748817
ChEMBLCHEMBL1201575